Other

Pfizer·Balance Sheet Statement·36 metrics

Breakdown

Metric	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Indefinite- lived intangible impairment	$126.6B	$126.5B	$123B	$122.8B	$123.2B	$122.7B	$126.2B	$126.4B
Gross Carrying Amount	$104B	$103.8B	$103.4B	$103.4B	$104.6B	$104.8B	$104B	$104.8B
Finite-Lived Intangible Assets, Accumulated Amortization	$65.4B	$66.5B	$67.5B	$68.8B	$70.5B	$71.3B	$72.5B	$73.9B
Trademarks	$22.6B	$22.6B	$19.6B	$19.4B	$18.7B	$17.8B	$22.2B	$21.6B
Long-term income taxes	$15B	$15B	—	$15B	$15B	$15B	—	$15B
Total accrued rebates and other sales-related accruals	$9.4B	$12.1B	$10.8B	$10.9B	$11.7B	$12.9B	$11.7B	$11.6B
Debt Securities, Amortized Cost Basis	$5.5B	$7.7B	$11.9B	$14.9B	$10.3B	$11.6B	$9.9B	$9.5B
Debt Securities Maturities, Next Twelve Months, Fair Value	$5.4B	$7.7B	—	$14.9B	$10.3B	$11.5B	—	$9.5B
Carrying values of hedged liabilities	—	—	—	—	—	—	$7.1B	$8.4B
Short-term debt and current portion of long-term debt	$11.9B	$9.7B	$6.9B	$4.5B	$4.3B	$4.3B	$3.2B	$3.9B
Current portion of long-term debt, principal amount	$3.8B	$3.8B	$3.8B	$3.8B	$4.3B	$4.3B	$3B	$3.9B
Liabilities, Noncurrent, Fair Value Disclosure	—	—	—	—	—	—	$2.7B	$3B
Deferred income taxes	$2.2B	$2.2B	$2.1B	$2.3B	$2.5B	$2.5B	$2.4B	$2.4B
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	—	—	$517M	$477M	—	—	$1.8B	$2B
Business Combination, Contingent Consideration, Liability, Noncurrent	—	—	—	—	—	—	$1.7B	$1.9B
Restructuring Reserve	$2.4B	$2.1B	$2.1B	$2.4B	$2B	$1.8B	$1.9B	$1.6B
Gross Assets/Liabilities	$1.2B	$1.5B	$1.4B	$1.3B	$1.9B	$1.6B	$1.5B	$1.4B
Derivative Liability	$1.2B	$1.5B	$1.4B	$1.3B	$1.9B	$1.6B	$1.5B	$1.4B
Collateral already posted, aggregate fair value	$764M	$917M	—	$640M	$1.1B	$1.2B	—	$1.2B
Other Assets, Noncurrent, Fair Value Disclosure	—	—	—	—	—	—	$1.1B	$1.1B
Derivative, Net Liability Position, Aggregate Fair Value	$775M	$910M	—	$646M	$1.1B	$1.1B	—	$1.1B
Insurance contracts	—	—	—	—	—	—	$999M	$950M
Fair value hedge adjustments on discontinued hedges	—	—	—	—	—	—	$821M	$803M
Private equity securities at cost	$786M	$759M	$719M	$712M	$729M	$690M	$696M	$688M
Allowance for doubtful accounts	$468M	$465M	$438M	$427M	$439M	$434M	$427M	$425M
Liabilities, Current, Fair Value Disclosure	—	—	—	—	—	—	$523M	$379M
Noncontrolling interests in subsidiaries	$275M	$272M	$294M	$299M	$317M	$295M	$299M	$303M
Cumulative amount of fair value hedging adjustment	—	—	—	—	—	—	-$163M	-$248M
Equity method investments (Note 11)	$8B	$8.6B	$217M	$224M	$224M	$223M	$235M	$237M
Derivatives	—	—	—	—	—	—	$116M	$155M
Long-term equity securities held in trust	—	—	—	—	—	—	$146M	$147M
Business Combination, Contingent Consideration, Liability, Current	—	—	—	—	—	—	$95M	$95M
Debt Securities Maturities, After Year Five, Fair Value	$22M	$21M	—	$21M	$34M	$33M	—	$38M
Debt Securities Maturities, Year Two Through Five, Fair Value	$101M	$33M	—	$26M	$14M	$16M	—	$10M
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$90M	$52M	$12M	$1M	$4M	$3M	$3M	$3M
Threshold for disclosure of proceedings under environmental laws	$1M	$1M	—	$1M	$1M	$1M	—	$1M